Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes - Takeaways - MDSpire

Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes

Lung cancer patients who take medications called GLP-1 receptor agonists — commonly prescribed for weight loss and diabetes management — fare better than those who don’t, according to research.

  • By

  • September 15, 2025

  • 3 min

Share

  • 1

    GLP-1 receptor agonists improve recurrence-free survival in lung cancer patients post-surgery.

  • 2

    Concurrent use of GLP-1RAs with immune checkpoint inhibitors enhances overall and progression-free survival.

  • 3

    Benefits of GLP-1RAs in lung cancer are primarily observed in overweight or obese patients.

  • 4

    The study suggests GLP-1RAs may enhance anti-tumor immunity by altering the tumor microenvironment.

  • 5

    GLP-1RAs, commonly used for weight loss and diabetes, could expand treatment options for non-small cell lung cancer.

Original Source(s)

Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes

  • by

  • September 15, 2025

Related Content

Editorial: Epigenetic modulation in cancer

Organ-specific pre-metastatic and metastatic niches in colorectal cancer: “discrepancy in response to immune checkpoint inhibitors in liver and lung metastasis”

Non-invasive radiogenomic mapping of the SMARCAL1-driven ferroptotic niche is associated with longitudinal MRD-negative surveillance in early-stage NSCLC